COYA Stock Forecast & Price Target

Coya Therapeutics Inc. demonstrates a robust financial performance with trailing twelve-month library revenues reaching $1 billion, highlighting a significant increase from $892 million the previous year, underscoring the demand for its premium content. The company’s strategic investment in a more profitable theatrical slate and the projected growth in television production are expected to enhance future profitability, particularly with anticipated increases in scripted series deliveries. Additionally, the company's historical tendency to trade at higher valuations compared to peers suggests a favorable outlook for improved valuation metrics moving forward.

Coya Therapeutics Inc. is facing financial challenges reflected in declining revenues and profitability, as the company reported a revenue drop to $475 million, falling short of estimates and year-over-year comparisons due to timing and volume issues in its media segment. The net loss for 3Q25 was $2.1 million, showing an improvement from the prior year but still indicating ongoing financial instability. Furthermore, the potential for new treatment methods in the biotechnology sector may pose a risk to Coya's product competitiveness, adding to concerns regarding its future market position.